Clinical trial · Interventional
Molecularly Tailored Therapy for Pancreas Cancer
A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer
NCT01888978CI-TRIAL-00032427completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patient therapy is tailored according to the molecular profile of the patient's tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FOLFIRI | Drug | FOLFIRI Regimen | ALIAS |
| Gem-5FU | Drug | — | UNRESOLVED |
| Gem-OX | Drug | — | UNRESOLVED |
| Gem-Tax | Drug | — | UNRESOLVED |
| Modified FOLFOX-6 | Drug | — | UNRESOLVED |
| Ox-Tax | Drug | — | UNRESOLVED |
| Tax-Iri | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- EXPERIMENTAL
- label
- Modified FOLFOX-6
- description
- Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
- interventionNames
- Drug: Modified FOLFOX-6
- type
- EXPERIMENTAL
- label
- Ox-Tax
- description
- Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
- interventionNames
- Drug: Ox-Tax
- type
- EXPERIMENTAL
- label
- FOLFIRI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven pancreatic adenocarcinoma with measurable disease * Biopsy accessible tumor deposits * ECOG performance status 0-2 * Age \>/= 18 years * Subjects with no brain metastases or history of previously treated brain metastases * Adequate hepatic, renal, and bone marrow function * Partial thromboplastin time must be \</= 1.5 x upper normal limit of institution's normal range and INR \< 1.5 * Life expectancy \> 12 weeks * Women of childbearing potential must have a negative seum pregnancy test within 14 days prior to initiation of treatment * Subject is capable of understanding and complying with parameters as outlines in the protocol and able to sign and date the consents Exclusion Criteria: * CNS metastases which do not meet criteria outlines in inclusion criteria * Active severe infection or known chronic infection with HIV or hepatitis B virus * Cardiovascular disease * Life threatening visceral disease or other severe concurrent disease * Women who are pregnant, breastfeeding, or women of childbearing potential not using dual forms of effective contraception * Anticipated patient survival under 3 months * Patients receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biological composition to gemcitabine, oxaliplatin, 5-FU, docetaxel or irinotecan * Uncontrolled intercurrent illness
References
Publications (0)
Data not yet available
No reference posted for this study.